The 60 mg vial size is intended to support extended, repeated, or high-volume laboratory protocols and does not represent a single human dosing level
The 2025 safety assessment of allulose by Food Standards Australia New Zealand concluded that, based on "the history of safe use of D-allulose internationally, the weight-of-evidence suggests adverse microbiological effects are unlikely." As noted by Daniel et al
There are multiple factors to find out if an antibody is being developed in the body
There is insufficient safety data on topical copper peptide use during pregnancy or breastfeeding, so it is advisable to consult your GP or pharmacist before using these products during either period
Watch out for disclaimers, such as for research only, not for humans, or safe for humans but not approved. These disclaimers state that the product is unregulated or unsafe